JP2024517760A - 抗５ｔ４抗体及びその使用 - Google Patents

抗５ｔ４抗体及びその使用 Download PDF

Info

Publication number
JP2024517760A
JP2024517760A JP2023566750A JP2023566750A JP2024517760A JP 2024517760 A JP2024517760 A JP 2024517760A JP 2023566750 A JP2023566750 A JP 2023566750A JP 2023566750 A JP2023566750 A JP 2023566750A JP 2024517760 A JP2024517760 A JP 2024517760A
Authority
JP
Japan
Prior art keywords
seq
nos
amino acid
acid sequences
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517760A5 (enExample
Inventor
ボギン，オレン
ダッサ，リアット
Original Assignee
イミュノリゾン リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノリゾン リミテッド filed Critical イミュノリゾン リミテッド
Publication of JP2024517760A publication Critical patent/JP2024517760A/ja
Publication of JP2024517760A5 publication Critical patent/JP2024517760A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023566750A 2021-05-04 2022-05-02 抗５ｔ４抗体及びその使用 Pending JP2024517760A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183636P 2021-05-04 2021-05-04
US63/183,636 2021-05-04
PCT/IL2022/050451 WO2022234570A1 (en) 2021-05-04 2022-05-02 Anti-5t4 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517760A true JP2024517760A (ja) 2024-04-23
JP2024517760A5 JP2024517760A5 (enExample) 2025-04-16

Family

ID=83932628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566750A Pending JP2024517760A (ja) 2021-05-04 2022-05-02 抗５ｔ４抗体及びその使用

Country Status (11)

Country Link
US (1) US20240228658A1 (enExample)
EP (1) EP4334362A4 (enExample)
JP (1) JP2024517760A (enExample)
KR (1) KR20240004837A (enExample)
CN (1) CN117279951A (enExample)
AU (1) AU2022270453A1 (enExample)
BR (1) BR112023023086A2 (enExample)
CA (1) CA3217716A1 (enExample)
IL (1) IL308203A (enExample)
MX (1) MX2023013018A (enExample)
WO (1) WO2022234570A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026510761A (ja) * 2023-03-08 2026-04-10 バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド 抗５ｔ４抗体及びその使用
WO2024208145A1 (zh) * 2023-04-03 2024-10-10 非同（成都）生物科技有限公司 抗5t4抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121633A1 (en) * 2010-07-16 2012-05-17 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
WO2016097408A1 (en) * 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
US20160251419A1 (en) * 2013-10-02 2016-09-01 The Rockefeller University Amyloid Protofibril Antibodies and Methods of Use Thereof
WO2019175198A2 (en) * 2018-03-12 2019-09-19 Genmab A/S Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121633A1 (en) * 2010-07-16 2012-05-17 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
US20160251419A1 (en) * 2013-10-02 2016-09-01 The Rockefeller University Amyloid Protofibril Antibodies and Methods of Use Thereof
WO2016097408A1 (en) * 2014-12-19 2016-06-23 Biotecnol Limited Fusion protein comprising three binding domains to 5t4 and cd3
WO2019175198A2 (en) * 2018-03-12 2019-09-19 Genmab A/S Antibodies

Also Published As

Publication number Publication date
MX2023013018A (es) 2024-01-18
WO2022234570A1 (en) 2022-11-10
IL308203A (en) 2024-01-01
BR112023023086A2 (pt) 2024-01-30
CN117279951A (zh) 2023-12-22
AU2022270453A1 (en) 2023-12-21
US20240228658A1 (en) 2024-07-11
KR20240004837A (ko) 2024-01-11
EP4334362A4 (en) 2025-04-16
EP4334362A1 (en) 2024-03-13
CA3217716A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
JP7222987B2 (ja) 抗ｒｏｒ１抗体とその作製及び使用方法
US20230072897A1 (en) Anti-b7-h4 antibody-drug conjugate and medicinal use thereof
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
ES2861925T3 (es) Anticuerpos que se dirigen al antígeno de maduración de células B y métodos de uso
CN111867630A (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
EP3744734A1 (en) Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
WO2022042719A1 (zh) 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途
CN113423736A (zh) 对muc18特异性的抗体
CN107735093A (zh) Cd123抗体和其结合物
JP2025134713A (ja) Ｐｄ１およびｖｅｇｆｒ２二重結合剤
CA3207791A1 (en) Anti-cd112r antibody and use thereof
KR20220167331A (ko) 항-flt3 항체 및 조성물
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
WO2023143535A1 (zh) 一种靶向il-18bp的抗体及其应用
US20240228658A1 (en) Anti-5t4 antibodies and uses thereof
CA3215704A1 (en) Antibodies binding trop2 and uses thereof
JP2025504496A (ja) 抗ｃｄ７３抗体及び使用
CA3091307A1 (en) Csf1r binding agents
WO2024088388A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
WO2024032761A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
EP4428154A1 (en) Anti-cldn18.2 antibody and use thereof
CN121079322A (zh) 抗cd27单克隆抗体及其应用
CN114276451B (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
EA053012B1 (ru) Антитела к 5t4 и варианты их применения
WO2024088386A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260707